SecBot SecBot
S-3 ·Filed Nov 9, 2026

TTRX

Turn Therapeutics Inc.
BEARISH
Impact 6/10
Horizonweeks Processed7d 16h ago SEC0001213900-26-117224
Shelf registration (potential dilution)
Actionable Insight ▼ Bearish

Monitor draw down activity under the GEM facility; each draw down at a 10% discount to market will pressure the stock. Watch for Phase 2b topline results for GX-03 in AD expected Q1 2027, which could alter the capital narrative.

DirectionBearish
Confidencehigh
Horizonweeks

GX-03

▲ Bullish Named in this S-3
Impact
Phase
Phase 2
Time to market
~3-4 years if Phase 2 succeeds; GX-03 needs Phase 3 trials (estimated $55-60M R&D spend per company guidance) and FDA approval. Cash runway only through Q1-Q3 2027, so additional financing likely needed.
Next catalyst
None dated

What to watchGX-03 Phase 2 topline data in Q4 2026 is the next binary inflection point. Interim data (June 2026) showed strong efficacy signals (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with zero serious adverse events. The expanded Stage 2 (~120-135 patients) and planned FDA Type-B meeting make Q4 the key catalyst window. Monitor enrollment updates and any competitive landscape shifts from approved topicals (ruxolitinib, roflumilast).

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$9.79
T+0 close · Nov 9, 2026 · via day close
Latest settled
−12.67%
T+5 · $8.55
Vs SPY
−10.97%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $9.79entry
  2. T+1 · 7d ago +1.33%α +1.70% · $9.92
  3. T+5 · 17h ago −12.67%α −10.97% · $8.55
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Turn Therapeutics filed an S-3 shelf registration to register the resale of 25,362,950 shares by selling stockholders, including up to 6,621,190 shares from GEM under an existing $85M committed equity facility. The company will not receive proceeds from the resale but may draw up to $85M from GEM for working capital. The registered shares represent 82.96% of outstanding shares, creating significant potential overhang. The filing coincides with a Q3 2026 net loss of $6.2M and $10.4M cash on hand, indicating a capital need.

Key Financial Metrics

Dilution
82.96%

Key Facts

  • S-3 registers resale of 25,362,950 shares, representing 82.96% of 30,572,704 shares outstanding as of Nov 6, 2026
  • Includes up to 6,621,190 shares from GEM under an $85M committed equity facility (GEM Purchase Agreement)
  • Company may receive up to $85M from future draw downs to GEM; $75M remains available after $4.07M initial draw and $2.72M second draw
  • GEM purchases shares at 90% of average daily closing price over 15-day pricing period, floor of $1.00 per share
  • Q3 2026 net loss of $6.2M vs $1.9M in Q3 2025; cash of $10.4M funds operations into Q3 2027 per prior 8-K
  • 9 offering/registration filings in last 24 months; pre-revenue clinical-stage biotech with no approved products

Financial Impact

Potential dilution of up to 82.96% of current shares outstanding; $85M equity facility available at 90% of market price

dilutionshare countcash balance

Risk Factors

  • Massive potential dilution: 25.36M registered shares vs 30.57M outstanding creates severe overhang
  • GEM facility pricing at 90% of market with $1.00 floor encourages repeated dilutive draws
  • Pre-revenue with widening losses ($6.2M in Q3 2026) and limited cash runway ($10.4M)
  • No approved products; clinical-stage risk with GX-03 Phase 2b data not expected until Q1 2027

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001213900-26-117224
Document: ea031087401ex-fee.htm0001213900-26-117224
Document: ea031087401ex5-1.htm0001213900-26-117224
Document: ea031087401ex23-1.htm0001213900-26-117224
Document: 0001213900-26-117224-index-headers.html0001213900-26-117224
Document: 0001213900-26-117224-index.html0001213900-26-117224
Document: 0001213900-26-117224.txt0001213900-26-117224

Track record

19 reports on TTRX

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +115.10% at T+60 after the May 18, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry $8.55 Now $8.55 −0.00% settles Feb 16
  2. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $9.92 Now $8.55 −13.81% settles Feb 8
  3. Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
  4. Nov 9, 20267d ago S-3 Bearish 6/10 Viewing Entry $9.79 Now $8.55 +12.67% settles Feb 5
  5. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $9.79 Now $8.55 −12.67% settles Feb 5
  6. Oct 19, 202628d ago DEF 14A Neutral 3/10 Entry $10.47 Now $8.55 −18.34% settles Jan 15
  7. Oct 6, 20265w ago 8-K Neutral 5/10 Entry $12.10 Now $8.55 −29.34% settles Jan 4
  8. Sep 10, 20269w ago 8-K Neutral 3/10 Entry $13.38 Now $8.55 −36.10% settles Dec 4
  9. Sep 9, 20269w ago 8-K Bullish 5/10 Entry $13.75 Now $8.55 −37.82% settles Dec 3
  10. Aug 18, 202612w ago 8-K Neutral 4/10 Entry $9.99 to $9.92 Now $8.55 −14.41% ▼ −0.70% +1.34% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 9h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026